On Wednesday, November 18, the final efficacy report for the Pfizer/BioNTech vaccine showed 95% efficacy, up from 94.5% for Moderna.
Pfizer still expects to produce 50 million doses of the vaccine this year and 1.3 billion doses by 2021.
Following the news, risk appetite in global markets was boosted again.
Gold jumped, U.S. stock futures rose, and British and U.S. oil both rose 2%. Pfizer U.S. shares rose nearly 4% pre-market, BioNTech SE rose more than 8% pre-market, and Moderna jumped pre-market.
Spot gold fell below the $1870 mark and is now at $1867.49/oz. Spot silver is down 1.0% on the day at $24.23/oz.
The three major U.S. stock index futures rose together, with Dow futures up 0.5%, S&P 500 stock index futures up 0.3%, and Nasdaq futures up 0.1%.
European markets were also upbeat. Europe’s Stoxx 50 index rose 0.4%, the Stoxx 600 index rose 0.4%; Germany, Spain and other major market stock indices have risen.
Brent crude oil and WTI crude oil prices are both up more than 1.8%.
Pfizer announced last week that its neocrown vaccine is more than 90% effective, although it must be stored and shipped at -70 degrees Celsius, a much lower temperature than competitor Moderna’s 2-8 degrees Celsius storage requirements.
Based on the overall size, demographic diversity, and immunization infrastructure of each state, Pfizer selected four states – Rhode Island, Texas, New Mexico, and Tennessee – for the pilot program. According to Pfizer, the four states will not receive vaccine earlier than other states as a result of the pilot.
States, cities and hospitals are scrambling for ultra-low-temperature refrigeration equipment to safely store the Pfizer-developed neocon vaccine. Refrigerator manufacturers are warning that demand for freezers is beginning to outstrip supply, and that supplies will take months to arrive.
On Monday, Nov. 16, Moderna reported that its Neocrown vaccine achieved 94.5 percent effectiveness in Phase III clinical trials, and that the Neocrown vaccine has a longer shelf life, lasting up to 30 days at refrigerated temperatures. By the end of 2020, Moderna expects to have approximately 20 million doses of mRNA-1273 available in the U.S. By 2021, the company expects to produce 500 million to 1 billion doses of mRNA-1273 worldwide.
Recent Comments